Literature DB >> 9316883

Phosphodiesterase inhibition improves agonist-induced relaxation of hypertensive pulmonary arteries.

R S Wagner1, C J Smith, A M Taylor, R A Rhoades.   

Abstract

Pulmonary artery (PA) relaxation in response to vasodilators is significantly attenuated in models of hypoxia-induced pulmonary hypertension (HPH). The activity of phosphodiesterases (PDE) which hydrolyze vasodilatory second messengers may be increased by HPH, which thereby contributes to attenuated vasodilatory responses. The purpose of this study was to determine the effect of PDE inhibition on agonist-induced relaxation of PA from normal rats and rats with HPH (F(IO2), 0.1 for 14 days). Isolated PA rings were suspended in baths containing Krebs-Henseliet salt solution and contracted with U46619 in the presence or absence of a PDE3 (milrinone) or PDE4 (rolipram) inhibitor. Isoproterenol and forskolin induced concentration-dependent relaxation of PA rings from normal rats and rats with HPH, but the degree of relaxation was significantly less (*P < .05; n = 4) in PA from rats with HPH. Treatment with either PDE inhibitor significantly improved (*P < .05; n = 4) the magnitude of agonist-induced relaxation in PA rings from normal rats and rats with HPH. Additionally, PDE3A transcripts (8 and 10 kb) were increased (3.8 +/- 1.6-fold and 3.9 +/- 1.2-fold; n = 3, respectively) in PAs from rats with HPH compared with normal controls. These data show that inhibition of PDE3 and PDE4 activity can significantly improve PA relaxation in HPH and that expression of PDE3A mRNA is increased during HPH. These findings suggest that PDEs play an important role in the development and maintenance of HPH.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9316883

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

1.  Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension.

Authors:  Fiona Murray; Margaret R MacLean; Nigel J Pyne
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

2.  Evidence for expression and function of phosphodiesterase type 5 (PDE-V) in rat resistance arteries.

Authors:  L J Sampson; J M Hinton; C J Garland
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

3.  Role of potassium channels and nitric oxide in the relaxant effects elicited by beta-adrenoceptor agonists on hypoxic vasoconstriction in the isolated perfused lung of the rat.

Authors:  J P Dumas; F Goirand; M Bardou; M Dumas; L Rochette; C Advenier; J F Giudicelli
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

4.  Milrinone attenuates thromboxane receptor-mediated hyperresponsiveness in hypoxic pulmonary arterial myocytes.

Authors:  K T Santhosh; O Elkhateeb; N Nolette; O Outbih; A J Halayko; S Dakshinamurti
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

5.  Targeting dimethylarginine dimethylaminohydrolases in pulmonary arterial hypertension: a new approach to improve vascular dysfunction?

Authors:  Jay L Zweier; M A Hassan Talukder
Journal:  Circulation       Date:  2011-03-07       Impact factor: 29.690

6.  Milrinone enhances relaxation to prostacyclin and iloprost in pulmonary arteries isolated from lambs with persistent pulmonary hypertension of the newborn.

Authors:  Satyan Lakshminrusimha; Nicolas F M Porta; Kathryn N Farrow; Bernadette Chen; Sylvia F Gugino; Vasanth H Kumar; James A Russell; Robin H Steinhorn
Journal:  Pediatr Crit Care Med       Date:  2009-01       Impact factor: 3.624

7.  Effect of sildenafil on cyclic nucleotide phosphodiesterase activity, vascular tone and calcium signaling in rat pulmonary artery.

Authors:  O Pauvert; C Lugnier; T Keravis; R Marthan; E Rousseau; J P Savineau
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

Review 8.  Phosphodiesterase inhibition in heart failure.

Authors:  Matthew Movsesian; Josef Stehlik; Fabrice Vandeput; Michael R Bristow
Journal:  Heart Fail Rev       Date:  2008-12-19       Impact factor: 4.214

9.  Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells.

Authors:  Ellena J Growcott; Karen G Spink; Xiaohui Ren; Saliha Afzal; Kathy H Banner; John Wharton
Journal:  Respir Res       Date:  2006-01-19

10.  Milrinone relaxes pulmonary veins in guinea pigs and humans.

Authors:  Annette D Rieg; Said Suleiman; Alberto Perez-Bouza; Till Braunschweig; Jan W Spillner; Thomas Schröder; Eva Verjans; Gereon Schälte; Rolf Rossaint; Stefan Uhlig; Christian Martin
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.